Bausch Fires Back At Mylan In Preliminary Patent Owner Response
ALEXANDRIA, Va. — A recent petition for inter partes review (IPR) of a patented oral dosage formulation used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome (IBS) should be...To view the full article, register now.
Already a subscriber? Click here to view full article